Significant decrease in efficacy against new Sarscov2 variants

alpha

visibility 431

Health

4/6/2021, 9:04:43 AM


0 likes 0 comments


While new dominant sarscov2 variants of concern taking over the globe, vaccine advocates continue to claim efficacy against dominant sarscov2 variants despite significant 2.2-6-8X decline in neutralizing antibody ability. Thle T cell immunity against now predominant new variants(B1351; P.1 etc) is overstated. The reality is vaccines efficacy drops to 15-33% from 90s%. The study shows very low numbers of predominantly t helpers cd4 providing intercellular signaling and infection memory, but not a real defense while cytotoxic cd8 cells are produced&circulate in extremely low concentration https://www.nature.com/articles/doi:10.1038/s41590-021-00902-8.epdf?sharing_token=y0WEgaoLdZnRuk9g3cScn9RgN0jAjWel9jnR3ZoTv0MjkRwSpMek28RzrR1zrK1KfgP9Fv2XayaBGNTV4T83CelAAdUn1jDf-HB7zsKC92ktZLD21Qw4RjogtiekUkjsVd-fpPsx8ZY5fe6wOEmOyPh47ChyU1b1BvVmnVEUKRo%3D